A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus

Skin Pruritus Clinical Trial

Official title: Multi Center, Double-blind, Randomized, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Antipruritic Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Skin Pruritus Patients

Status Completed

Clinical Trial Summary

The study is a Phase II, multi center, randomized, double-blind, placebo-controlled study in male and female subjects, aged ≥ 19 years with skin pruritus. All subjects will receive BID topical applications of PAC-14028 cream or vehicle for up to 4 weeks.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pruritus
• Skin Pruritus

• NCT number: NCT02565134
• Study type: Interventional
• Source: Amorepacific Corporation
• Status: Completed
• Phase: Phase 2
• Start date: October 2014
• Completion date: July 2016